Andrew Brackmann, an analyst from William Blair, has initiated a new Buy rating on Natera (NTRA).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Andrew Brackmann has given his Buy rating due to a combination of factors that underscore Natera’s position as a core long-term growth holding. He highlights the company’s leadership in major diagnostic markets, particularly molecular and minimal residual disease testing, along with a broadening product portfolio that benefits from rising adoption and improving pricing, supporting a path to attractive margin expansion.
He also notes that although Natera trades at a premium valuation versus peers, this is justified by its scale, first-mover advantage in MRD, and substantial long-term earnings potential. Brackmann further points to a large underpenetrated MRD market, a pipeline rich in clinical evidence generation, early detection initiatives, women’s health expansion, and AI partnerships, all of which can unlock additional upside beyond current growth expectations.
In another report released on April 7, Citi also maintained a Buy rating on the stock with a $300.00 price target.